B of A Securities Maintains Buy on Elevance Health, Raises Price Target to $646
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Kevin Fischbeck maintains a Buy rating on Elevance Health (NYSE:ELV) and raises the price target from $621 to $646.
June 04, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities analyst Kevin Fischbeck maintains a Buy rating on Elevance Health and raises the price target from $621 to $646.
The Buy rating and increased price target from a reputable analyst at B of A Securities is likely to positively influence investor sentiment and drive short-term price appreciation for Elevance Health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100